Description
AV-SYNERGY: BPC-157 + KPV Research Peptide Formulation
AV-SYNERGY is an Aevigenix branded research formulation listed as containing two synthetic peptide compounds, BPC-157 and KPV. The product is presented in a 90-count capsule format for nonclinical laboratory research.
The listed formulation identifies 500 mcg of BPC-157 and 500 mcg of KPV. The precise composition, quantity basis, and analytical characteristics of individual production batches should be confirmed through applicable supplier documentation.
Research Compound Overview
BPC-157 and KPV are distinct peptide sequences investigated in experimental research. Each has its own molecular structure and analytical characteristics.
BPC-157: A synthetic peptide consisting of 15 amino acid residues. Laboratory characterization may include sequence verification, molecular mass analysis, and purity assessment.
KPV: A tripeptide consisting of lysine, proline, and valine. Its short peptide sequence can be evaluated using analytical methods appropriate for peptide identification and characterization.
Peptide Structure and Composition
Peptides are composed of amino acids connected by peptide bonds. Differences in sequence length, amino acid composition, and chemical modifications contribute to the molecular characteristics of individual compounds.
BPC-157 is classified as a pentadecapeptide, while KPV is a tripeptide. The presence of both compounds in a research formulation requires analytical methods capable of distinguishing their respective identities and quantities.
Analytical Characterization
Laboratory evaluation of peptide materials may involve analytical techniques selected according to the research objective, sample composition, and available instrumentation.
- Identity: Verification of the individual peptide components.
- Composition: Assessment of the stated formulation constituents.
- Purity: Evaluation of peptide-related impurities using suitable analytical methods.
- Quantity: Confirmation of the stated amounts using validated analytical procedures.
- Batch Consistency: Comparison of relevant analytical characteristics between production lots.
Analytical methods and acceptance criteria should be selected by qualified laboratory personnel. The availability of particular testing results must be confirmed through batch-specific documentation.
Product Format and Documentation
AV-SYNERGY is listed in a 90-count capsule format. The capsule composition, inactive ingredients, and exact quantity of each peptide per capsule require verification against the applicable product specifications.
Supplier documentation and Certificates of Analysis, where available, should be reviewed to establish the identity, composition, and analytical characteristics of the supplied research material.
Frequently Asked Questions
AV-SYNERGY is listed as a combination research formulation containing BPC-157 and KPV. These are two distinct synthetic peptide sequences.
BPC-157 is a 15-residue peptide, whereas KPV consists of three amino acid residues: lysine, proline, and valine.
AV-SYNERGY is listed as a 90-count capsule research formulation. Product-specific composition and quantity information should be verified against supplier documentation.
Documentation availability depends on the applicable production batch. Customers should request verified analytical information when required for their research.
AV-SYNERGY is designated exclusively for lawful nonclinical laboratory research. Not intended for human consumption, oral administration, therapeutic use, or veterinary use. Product identity, composition, and purity require confirmation through appropriate batch-specific documentation.

